IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art

Serial No.:

Unit:

1623

Filing Date:

1/21/99

09/234,532

Examiner:

Howard Owens, Jr.

Inventor:

Dr. Alfred T. Sapse

Title:

COMPOSITION OF ANTI-HIV DRUGS AND ANTI-CORTISOL

COMPOUNDS AND METHOD FOR DECREASING THE SIDE EFFECTS OF

ANTI-HIV DRUGS IN A HUMAN

Box Non-Fee Amendment Assistant Commissioner for Patents Washington, D.C. 20231

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8 (A)

Date of Deposit:

PRELIMINARY AMENDMENT TO PATENT APPLICATION

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first-class mail in an envelope addressed to Box Non-Fee Amendment Assistant Commissioner for Patents, Washington, D.C. 20231.

Joda K Prince

## Dear Sir:

The following preliminary amendment and remarks are in response to the Examiner's Advisory Action mailed on May 30, 2000. Applicant hereby requests continued examination and reconsideration of the application, in view of the following amendments and remarks.

#12/C 7-14-00 Donne

Under the Paperwork Reduction Ac

07-05-00

GAU1623

PTO/SB/29 (8/98) Approved for use through 09/30/2000. OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE required to respond to a collection of information unless it displays a valid OMB control number

## CONTINUED PROSECUTION APPLICATION (CPA) **REQUEST TRANSMITTAL**

Submit an original, and a duplicate for fee processing. (Only for Continuation or Divisional applications under 37 C.F.R. § 1. 53(d)) CHECK BOX, if applicable:

DUPLICATE

Additions to: stant Commissioner for Patents Box CPA Washington, DC 20231

Attorney Docket No. of Prior Application	SAP 1398-002C
First Named Inventor	Sapse
Examiner Name	Howard Owens, Jr.
Group I Art Unit	1623
Express Mail Label No.	EL039916739US

;	
	This is a request for a continuation or divisional application under 37 C.F.R. § 1.53(d),
	(continued prosecution application (CPA)) of prior application number 09 / 234,532 filed on January 21, 1999, entitled effects of anti-HIV drugs and anti-contisol. compounds and method for decreasing the side 082
	NOTES NOTES
	FILING QUALIFICATIONS: The prior application identified above must be a nonprovisional application that is either (1) complete as defined by 37 C.F.R. § 1. 51(b), or (2) the national stage of an international application in compliance with 35 U.S.C. 371.  A Notice will be placed on a patent issuing from a CPA, except for reissues and designs, to the effect that the patent issued on a CPA and is subject to the twenty-year patent term provisions of 35 U.S.C. § 154(a)(2). Therefore, the prior application of a CPA may have been filed before, on or after June 8, 1995.
1	C-I-P NOT PERMITTED: A continuation-in-part application cannot be filed as a CPA under 37 C.F.R. § 1.53(d), but must be filed under 37 C.F.R. § 1.53(b).
ř	EXPRESS ABANDONMENT OF PRIOR APPLICATION: The filing of this CPA is a request to expressly abandon the prior application as of the filing date of the request for a CPA. 37 C.F.R. § 1.53(b) must be used to file a continuation, divisional, or continuation-in-part of an application that is not to be abandoned.
	ACCESS TO PRIOR APPLICATION: The filing of this CPA will be construed to include a waiver of confidentiality by the applicant under 35 U. S. C. 122 to the extent that any member of the public who is entitled under the provisions of 37 C.F.R. § 1. 14 to access to, copies of, or information concerning, the prior application may be given similar access to, copies of, or similar information or applications in the file jacket.
	35 U.S.C. 120 STATEMENT: In a CPA, no reference to the prior application is needed in the first sentence of the specification and none should be submitted. If a sentence referencing the prior application is submitted, it will not be entered. A request for a CPA is the specific reference required by 35 U.S.C. 120 and to every application assigned the application number identified in such request, 3 7 C.F. R. § 1. 78(a).
	t. Enter the unentered amendment previously filed on under 37 C.F.R. § 1. 1 16 in the prior nonprovisional application.  2. X A preliminary amendment is enclosed.
	3. This application is filed by fewer than all the inventors named in the prior application, 37 C.F.R. § 1.53 (d)(4)
07/06/2000 SLO	ANG1 a0(00)009日9至745我he following inventor(s) named in the prior nonprovisional application:
01 FC:231	345.00-OP
. •	b. The inventor(s) to be deleted are set forth on a separate sheet attached hereto.  4. A new power of attorney or authorization of agent (PTO/SB/81) is enclosed.
	Information Disclosure Statement (IDS) is enclosed:     a. PTO-1449     b. Copies of IDS Citations

[Page 1 of 2]

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box CPA, Washington, DC 20231.

PTO/SB/29 (8/98)
Approved for use through 09/30/2000. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

							•		
CLAIMS	(1) FOR	(2) NUMBER I	FILED	(3) NUMBE	R EXTRA	(4) F	RATE	(5) CALCULATIONS	
	TOTAL CLAIMS	10 2	0 -				_		
	1. 1 6(c) or 0))	10 -2	:0 =	0		× \$	:		
	INDEPENDENT CLAIMS	2 -3	** =	0		x \$			
	MULTIPLE DEPENDENT	CLAIMS (if app	plicable)	(37 C.F.R. § 1.	16(d))	+ \$	:		
	BASIC FEE (37 C.F.R. §1.16)							690	
		690							
	Reduction by 50% for filin	345							
	* Reissue claims in excess ** Reissue independent cla					T	OTAL =	345	
Deposi a	The prior applic UNLESS a new	6 7 C.F.R. § 1. 7 C.F.R. § 1. 7 C.F.R. § 1. 8 345 mber, if designment will carry of Transmitted and (Should be extion's corre	1 6. 1.17. 1 8. ired over to this I CPA especific	is enclos SAP 1398-( is CPA unless a (PTO/SB/2) cally itemized, ence addre ddress is pre	sed. 002C new Attorney 9A) See MPEP 9 ss will carr ovided belo	Docket Nu 503) 	mber has	been provided herein.]	
Custome	er Number or Bar Code Label	(insert Custome	er No. or	Attach bar code	label here) 	or 🛛	] New co	orrespondence address below	
Name									
	Cheryl S. Scotney								
Addross	Standley & Gilcrest LLP								
Address	495 Metro Place South, Suite 210								
City	Dublin		State	Ohio		Zip Co	de 43	3017-5319	
Country	USA	Tel	lephone	(614) 792	2-5555		Fax (6	514) 792-5536	

13. SIGNATURE O	F APPLICANT, ATTORNEY, OR AGENT REQUIRED
Name (Print/Type)	Cheryl S. Scotney
Signature	Clary S Scotney
Registration No. (Attorney/Agent)	46,218
Date	07/03/2000